Loading
A phase 2 trial of Apalutamide in prostate cancer, run by Monte Rosa Therapeutics, Inc, now recruiting.
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer is a phase 2 interventional study registered as NCT07745361 by Monte Rosa Therapeutics, Inc, with 25 participants planned, started 2026-08 and due to reach its primary completion in 2027-10. Interventions recorded: Oral MRT-2359, Apalutamide. Conditions listed: Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Monte Rosa Therapeutics, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/